In Vitro and In Vivo Neutralizing Efficacy of Monoclonal Antibodies Against Sars-Cov-2 Variants in Kidney Transplant Recipients
Mots clés
sotrovimab
COVID-19
immunocompromised
kidney transplant recipients
monoclonal antibodies
SARS-CoV-2 BAU
binding arbitrary units COVID-19
coronavirus disease 2019 KTRs
kidney transplant recipients SARS-CoV-2
severe acute respiratory syndrome coronavirus 2 mAbs
binding arbitrary units
coronavirus disease 2019
KTRs
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
mAbs
Domaines
Urologie et NéphrologieOrigine | Publication financée par une institution |
---|---|
licence |